Tertiary Screen
Tertiary Screen - Related Videos
01:21
Tertiary Healthcare System
0 Views •
2023
Specialized care provided over an extended period is called tertiary care. Usually, a primary or secondary care physician will refer a patient to tertiary care. A patient's maximum physical and mental function is restored in tertiary care, which is caused due to the impact of a chronic illness or condition. Tertiary care aims to achieve the highest level of functioning possible while managing chronic illness. For example, a patient who falls and fractures their hip will need secondary care to...
01:12
Nomenclature of Secondary and Tertiary Amines
0 Views •
2025
The secondary and tertiary amines are derivatives of ammonia, where two and three of its hydrogens are replaced by alkyl groups, respectively. Secondary and tertiary amines can be symmetrical with identical alkyl groups attached to the nitrogen atom or unsymmetrical when more than one type of alkyl group is present. The standard nomenclature of secondary and tertiary amines is similar to the names given to the primary amines. They are generally named alkylamines. As depicted in Figure 1, for...
13:37
Split-and-pool Synthesis and Characterization of Peptide Tertiary Amide Library
0 Views •
Cited by 5 •
2014
Peptide tertiary amides (PTAs) are a superfamily of peptidomimetics that include but are not limited to peptides, peptoids and N-methylated peptides. Here we describe a synthetic method which combines both split-and-pool and sub-monomer strategies to synthesize a one-bead one-compound library of PTAs.
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
0 Views •
2015
Here we describe a cell-based reporter gene assay as a valuable tool to screen chemical libraries for compounds modulating post-transcriptional control mechanisms exerted through 3’ UTR.
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
FAQs
Concentration-response measurements show how activity changes as candidate exposure increases. In a tertiary screen, this pattern helps estimate potency, meaning the amount needed to produce an effect, while comparisons across targets or systems can reveal selectivity. These results provide a more informative basis for ranking hits than a single activity measurement.
Moving from simpler primary or secondary assays into a more complex or physiologically relevant system can reveal whether a hit retains activity under conditions that better represent biology. This comparison helps separate effects that depend on a simplified assay format from responses that remain meaningful in the selected cellular or molecular context.
Reproducibility matters because an apparent hit can arise from an assay artifact rather than a meaningful biological effect. Repeating and comparing responses in the tertiary stage helps investigators judge whether activity persists and whether it is sufficiently consistent to support further evaluation. This reduces the risk of advancing misleading candidates.
Assessing mechanism of action alongside toxicity adds context to a candidate's observed activity. Mechanistic information indicates how the candidate may produce a response, whereas toxicity testing identifies harmful effects within the evaluated system. Considering both dimensions helps distinguish a useful biological effect from activity that lacks an acceptable safety profile.
Investigators first carry selected hits forward from primary and secondary assays, then test them in the chosen complex or physiologically relevant system. They collect concentration-response data and examine potency, selectivity, mechanism of action, toxicity, or activity against defined targets. The resulting evidence supports a structured decision about which candidates merit continued study.
In drug discovery, tertiary screening narrows the candidate set before animal studies or advanced development. By prioritizing compounds with more convincing activity and by exposing weaknesses such as poor selectivity, unclear mechanism, toxicity, or assay-dependent effects, the process guides lead optimization. It therefore helps allocate later experiments toward candidates with stronger therapeutic potential.